Does J0896 require prior authorization?

Yes, J0896 requires prior authorization (high confidence). At least one active policy explicitly requires prior authorization.

What is the Medicare reimbursement rate for J0896?

Medicare facility rate: N/A. Non-facility rate: N/A. Work RVU: 0.00.

Backwork Sign up free

`J0896`, Injection, luspatercept-aamt, 0.25 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

At least one active policy explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

For beta thalassemia: medical record documentation demonstrating diagnosis of anemia due to beta thalassemia (including beta+ thalassemia, beta0 thalassemia, hemoglobin E/beta thalassemia), age ≥18, and transfusion history in the previous 24 weeks showing at least six units PRBC and no transfusion-free period greater than 35 days.
For MDS: documentation of symptomatic anemia due to MDS; IPSS-R risk classification showing Very Low, Low, or Intermediate risk; documentation that del(5q) mutation is not present.
For MDS ring sideroblast criteria: laboratory/pathology report documenting ring sideroblast percentage and/or documentation of SF3B1 mutation status, and serum erythropoietin (EPO) level when applicable (showing ≤ 500 mU/mL if RS <15% or <5% with SF3B1 mutation).
For MDS/MPN: documentation of diagnosis of MDS/MPN, presence of SF3B1 mutation, and platelet count demonstrating thrombocytosis (platelet count ≥ 450 × 10^9 / L).
For myelofibrosis-associated anemia: documentation of diagnosis, presence or absence of symptomatic splenomegaly and/or constitutional symptoms, and if symptomatic splenomegaly/constitutional symptoms present, documentation that Reblozyl will be used in combination with a JAK inhibitor (name of JAK inhibitor).
Provider specialty documentation: prescription by, or documentation of consultation with, a hematologist, oncologist, or other specialist with expertise in the diagnosis and management of the applicable condition for which Reblozyl is being prescribed.

Key Coverage Criteria

Anemia in adult patients with beta thalassemia who meet all of the following criteria: Diagnosis of anemia due to beta thalassemia including beta+ thalassemia, beta0 thalassemia, and hemoglobin E/beta thalassemia; Patient is 18 years of age or older; Patient is transfusion dependent as evidenced by both of the following in the previous 24 weeks: Has required regular transfusion of at least six units of packed red blood cells (PRBC); and No transfusion free period greater than 35 days; Prescribed [...]
Treatment of symptomatic anemia in patients with myelodysplastic syndromes (MDS) who meet all of the following criteria: Diagnosis of symptomatic anemia due to myelodysplastic syndrome (MDS); Patient has lower risk disease as defined as International Prognostic Scoring System (IPSS-R): Very Low, Low, Intermediate; Patient does not have a confirmed mutation with deletion 5q [del(5q)]; One of the following: (a) Both of the following: Ring sideroblasts < 15% (or ring sideroblasts <5% with an SF3B1 [...]
Anemia in patients with myelodysplastic syndrome/myeloproliferative overlap neoplasm (MDS/MPN) who meet all of the following criteria: Diagnosis of anemia due to myelodysplastic syndrome/myeloproliferative overlap neoplasm (MDS/MPN); Presence of a SF3B1 mutation; Thrombocytosis defined as platelet count ≥ 450 × 10^9 / L; Prescribed by, or in consultation with, a hematologist, oncologist, or other specialist with expertise in the diagnosis and management of MDS/MPN; Dosing is in accordance with t [...]
Myelofibrosis-associated anemia in patients who meet all of the following criteria: Diagnosis of myelofibrosis-associated anemia; One of the following: (a) Both of the following: Symptomatic splenomegaly and/or constitutional symptoms AND Used in combination with a JAK inhibitor (e.g., Inrebic (fedratinib), Jakafi (ruxolitinib), Ojjaara (momelotinib), Vonjo (pacritinib)); OR (b) No splenomegaly or constitutional symptoms. [...]
UnitedHealthcare recognizes indications and uses of injectable oncology medications, including therapeutic radiopharmaceuticals, listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary (i.e., Reblozyl uses appearing in NCCN with these categories are recognized as covered).
Medically necessary when the drug is FDA‑approved and administered in accordance with FDA labeling for an oncologic indication.

20 Active Policies

ARKBLUE-LUSPATERCEPT-AAMT-E-G-REBLOZYL-286383C0A7, Luspatercept-aamt (e.g., Reblozyl)

BCBSLA-00703-BD451A00EB, 00703 luspatercept-aamt (Reblozyl)

BCBSM-2117666-06B781FFC0, REBLOZYL (LUSPATERCEPT-AAMT)

BCBSMS-S-5-01-552-A78C9F9405, State and School Employees' Health Insurance Plan - Reblozyl (luspatercept-aamt)

BCBSMS-L-5-01-552-BC5180718B, Reblozyl (luspatercept-aamt)

POINT32HEALTH-MDMNG-13566, Reblozyl (luspatercept-aamt)

MULTI

HEALTHPARTNERS-CC-ENTRY-226974, Oncology - luspatercept-aamt (Reblozyl) and imetelstat (Rytelo)

MULTI

POINT32HEALTH-MDMNG-13576, Reblozyl (luspatercept-aamt)

MULTI

BCBSND-LUSPATERCEPT-REBLOZYL-09F241D309, Luspatercept Reblozyl

BCBSNE-X-156-0BF53CB361, LUSPATERCEPT-AAMT (REBLOZYL) (PREAUTHORIZATION REQUIRED)

BCBSNJ-DRUGS-196-CF98A8E728, Luspatercept-aamt (Reblozyl)

MODA-REBLOZYL-6D1E259D54, Reblozyl (luspatercept-aamt)

HEALTHNET_OR-HNOR-LUSPATERCEPT-AAMT-REBLOZYL-CP-PHAR-450-054286B346, Luspatercept-aamt (Reblozyl); CP.PHAR.450

IBX-MEDICARE-ADVANTAGE-MA08-110E-50EDFE6E9D, Luspatercept–aamt (Reblozyl)

IBX-COMMERCIAL-08-00-10E-63B4C2FFB0, Luspatercept–aamt (Reblozyl)

UHC-EXCH-MD-REBLOZYL-LUSPATERCEPT-AAMT-COMMERCIAL-AN-56DFA3EE31, Reblozyl (Luspatercept-Aamt) – Commercial and Individual Exchange Medical Benefit Drug Policy

EVICORE-HPLAN-HEALTH_PARTNERS_PLANS-4BC80209CCC5, Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List

UHC-POL-reblozyl, Reblozyl (Luspatercept-Aamt)

BCBSIL-RX502.061, Oncology Medications

BCBSMT-RX502.061, Oncology Medications

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J0896 Sign up free

J0896, Injection, luspatercept-aamt, 0.25 mg

HCPCS/CPT

Prior Authorization

Prior Auth Required

At least one active policy explicitly requires prior authorization (high confidence)

Medicare Pricing

Work RVU

0.00

Facility

N/A

Non-Facility

N/A

Documentation Required

For beta thalassemia: medical record documentation demonstrating diagnosis of anemia due to beta thalassemia (including beta+ thalassemia, beta0 thalassemia, hemoglobin E/beta thalassemia), age ≥18, and transfusion history in the previous 24 weeks showing at least six units PRBC and no transfusion-free period greater than 35 days.
For MDS: documentation of symptomatic anemia due to MDS; IPSS-R risk classification showing Very Low, Low, or Intermediate risk; documentation that del(5q) mutation is not present.
For MDS ring sideroblast criteria: laboratory/pathology report documenting ring sideroblast percentage and/or documentation of SF3B1 mutation status, and serum erythropoietin (EPO) level when applicable (showing ≤ 500 mU/mL if RS <15% or <5% with SF3B1 mutation).
For MDS/MPN: documentation of diagnosis of MDS/MPN, presence of SF3B1 mutation, and platelet count demonstrating thrombocytosis (platelet count ≥ 450 × 10^9 / L).
For myelofibrosis-associated anemia: documentation of diagnosis, presence or absence of symptomatic splenomegaly and/or constitutional symptoms, and if symptomatic splenomegaly/constitutional symptoms present, documentation that Reblozyl will be used in combination with a JAK inhibitor (name of JAK inhibitor).
Provider specialty documentation: prescription by, or documentation of consultation with, a hematologist, oncologist, or other specialist with expertise in the diagnosis and management of the applicable condition for which Reblozyl is being prescribed.

Key Coverage Criteria

Anemia in adult patients with beta thalassemia who meet all of the following criteria: Diagnosis of anemia due to beta thalassemia including beta+ thalassemia, beta0 thalassemia, and hemoglobin E/beta thalassemia; Patient is 18 years of age or older; Patient is transfusion dependent as evidenced by both of the following in the previous 24 weeks: Has required regular transfusion of at least six units of packed red blood cells (PRBC); and No transfusion free period greater than 35 days; Prescribed [...]
Treatment of symptomatic anemia in patients with myelodysplastic syndromes (MDS) who meet all of the following criteria: Diagnosis of symptomatic anemia due to myelodysplastic syndrome (MDS); Patient has lower risk disease as defined as International Prognostic Scoring System (IPSS-R): Very Low, Low, Intermediate; Patient does not have a confirmed mutation with deletion 5q [del(5q)]; One of the following: (a) Both of the following: Ring sideroblasts < 15% (or ring sideroblasts <5% with an SF3B1 [...]
Anemia in patients with myelodysplastic syndrome/myeloproliferative overlap neoplasm (MDS/MPN) who meet all of the following criteria: Diagnosis of anemia due to myelodysplastic syndrome/myeloproliferative overlap neoplasm (MDS/MPN); Presence of a SF3B1 mutation; Thrombocytosis defined as platelet count ≥ 450 × 10^9 / L; Prescribed by, or in consultation with, a hematologist, oncologist, or other specialist with expertise in the diagnosis and management of MDS/MPN; Dosing is in accordance with t [...]
Myelofibrosis-associated anemia in patients who meet all of the following criteria: Diagnosis of myelofibrosis-associated anemia; One of the following: (a) Both of the following: Symptomatic splenomegaly and/or constitutional symptoms AND Used in combination with a JAK inhibitor (e.g., Inrebic (fedratinib), Jakafi (ruxolitinib), Ojjaara (momelotinib), Vonjo (pacritinib)); OR (b) No splenomegaly or constitutional symptoms. [...]
UnitedHealthcare recognizes indications and uses of injectable oncology medications, including therapeutic radiopharmaceuticals, listed in the NCCN Drugs and Biologics Compendium with Categories of Evidence and Consensus of 1, 2A, and 2B as proven and medically necessary (i.e., Reblozyl uses appearing in NCCN with these categories are recognized as covered).
Medically necessary when the drug is FDA‑approved and administered in accordance with FDA labeling for an oncologic indication.

20 Active Policies

ARKBLUE-LUSPATERCEPT-AAMT-E-G-REBLOZYL-286383C0A7, Luspatercept-aamt (e.g., Reblozyl)

BCBSLA-00703-BD451A00EB, 00703 luspatercept-aamt (Reblozyl)

BCBSM-2117666-06B781FFC0, REBLOZYL (LUSPATERCEPT-AAMT)

BCBSMS-S-5-01-552-A78C9F9405, State and School Employees' Health Insurance Plan - Reblozyl (luspatercept-aamt)

BCBSMS-L-5-01-552-BC5180718B, Reblozyl (luspatercept-aamt)

POINT32HEALTH-MDMNG-13566, Reblozyl (luspatercept-aamt)

MULTI

HEALTHPARTNERS-CC-ENTRY-226974, Oncology - luspatercept-aamt (Reblozyl) and imetelstat (Rytelo)

MULTI

POINT32HEALTH-MDMNG-13576, Reblozyl (luspatercept-aamt)

MULTI

BCBSND-LUSPATERCEPT-REBLOZYL-09F241D309, Luspatercept Reblozyl

BCBSNE-X-156-0BF53CB361, LUSPATERCEPT-AAMT (REBLOZYL) (PREAUTHORIZATION REQUIRED)

BCBSNJ-DRUGS-196-CF98A8E728, Luspatercept-aamt (Reblozyl)

MODA-REBLOZYL-6D1E259D54, Reblozyl (luspatercept-aamt)

HEALTHNET_OR-HNOR-LUSPATERCEPT-AAMT-REBLOZYL-CP-PHAR-450-054286B346, Luspatercept-aamt (Reblozyl); CP.PHAR.450

IBX-MEDICARE-ADVANTAGE-MA08-110E-50EDFE6E9D, Luspatercept–aamt (Reblozyl)

IBX-COMMERCIAL-08-00-10E-63B4C2FFB0, Luspatercept–aamt (Reblozyl)

UHC-EXCH-MD-REBLOZYL-LUSPATERCEPT-AAMT-COMMERCIAL-AN-56DFA3EE31, Reblozyl (Luspatercept-Aamt) – Commercial and Individual Exchange Medical Benefit Drug Policy

EVICORE-HPLAN-HEALTH_PARTNERS_PLANS-4BC80209CCC5, Q3 - 2026 Jefferson Health Plans MedOnc Master Drug List

UHC-POL-reblozyl, Reblozyl (Luspatercept-Aamt)

BCBSIL-RX502.061, Oncology Medications

BCBSMT-RX502.061, Oncology Medications

Have a follow-up question?

Ask Backwork about documentation requirements, denial risks, or coverage in your state.

Ask Backwork about J0896 Sign up free

`J0896`, Injection, luspatercept-aamt, 0.25 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`J0896`, Injection, luspatercept-aamt, 0.25 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

J0896, Injection, luspatercept-aamt, 0.25 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

J0896, Injection, luspatercept-aamt, 0.25 mg

Prior Authorization

Medicare Pricing

Documentation Required

Key Coverage Criteria

20 Active Policies

Related Codes

Have a follow-up question?

`J0896`, Injection, luspatercept-aamt, 0.25 mg

`J0896`, Injection, luspatercept-aamt, 0.25 mg